Treatment with APS could resist the infection of the pathogen Brucella and alleviate the symptoms of mice with brucellosis by activating the macrophages and upregulating the production of TNF-α, IL-12, and IFN-γ (Shi et al., 2019). The gene discussed is TNF; the disease is brucellosis.